^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Lung Non-Small Cell Squamous Cancer

    Related cancers:
    3d
    A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors (clinicaltrials.gov)
    P1/2, N=180, Recruiting, Alentis Therapeutics AG
    Trial initiation date
    7d
    EVOKE-01: Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=603, Active, not recruiting, Gilead Sciences | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    docetaxel • Trodelvy (sacituzumab govitecan-hziy)
    9d
    BNT326-02: A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1/2, N=420, Recruiting, BioNTech SE
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • ALK rearrangement • PD-L1 negative • RET mutation • MET mutation • EGFR negative
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pumitamig (BNT327) • BNT326 • MK-3475 SC
    9d
    DARWIN II: Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (clinicaltrials.gov)
    P2, N=50, Completed, University College, London | Active, not recruiting --> Completed | Trial completion date: May 2026 --> Nov 2025 | Trial primary completion date: May 2026 --> Nov 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene)
    |
    HER-2 amplification • BRAF V600 • RET fusion • ALK fusion
    |
    Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • carboplatin • Alecensa (alectinib) • Kadcyla (ado-trastuzumab emtansine)
    12d
    BEACON-Lung: Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Sichuan Cancer Hospital and Research Institute
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    carboplatin • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel
    14d
    POD1UM-304: Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=583, Active, not recruiting, Incyte Corporation | Completed --> Active, not recruiting
    Enrollment closed
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Zynyz (retifanlimab-dlwr)
    14d
    PERSEE: PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % (clinicaltrials.gov)
    P3, N=349, Active, not recruiting, University Hospital, Brest | Completed --> Active, not recruiting
    Enrollment closed • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • paclitaxel
    14d
    ALTAIR: A Platform Study in Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P1/2, N=152, Recruiting, AstraZeneca | N=56 --> 152
    Enrollment change • Trial initiation date
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • carboplatin • albumin-bound paclitaxel • Cyramza (ramucirumab) • pemetrexed • rilvegostomig (AZD2936)
    14d
    S0533: Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    Avastin (bevacizumab) • cisplatin • docetaxel • etoposide IV • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    16d
    Trofuse-023: Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (clinicaltrials.gov)
    P3, N=851, Recruiting, Merck Sharp & Dohme LLC | N=301 --> 851
    Enrollment change
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • Jiataile (sacituzumab tirumotecan)
    16d
    National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=423, Completed, University of Birmingham | Active, not recruiting --> Completed
    Trial completion • IO biomarker
    |
    NKX2-1 (NK2 Homeobox 1) • TP63 (Tumor protein 63)
    |
    Xalkori (crizotinib) • Tagrisso (osimertinib) • Ibrance (palbociclib) • Imfinzi (durvalumab) • docetaxel • Koselugo (selumetinib) • Truqap (capivasertib) • fexagratinib (ABSK091) • ceralasertib (AZD6738) • sitravatinib (MGCD516) • vistusertib (AZD2014)
    19d
    Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2) (clinicaltrials.gov)
    P2, N=18, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation
    |
    albumin-bound paclitaxel • retlirafusp alfa (SHR-1701)